Get the Stockscreener App
0.2275
3.08%
-0.00045
Virax Biolabs Group Ltd Stock (VRAX) Forecast
The Virax Biolabs Group Ltd (VRAX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $15.87, representing a +6,876% increase from the current price of $0.2275. The highest analyst price target is $15.53, and the lowest is $16.21.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month VRAX Price Target
Average 13.43
(+5,803% Upside)
Is Virax Biolabs Group Ltd (VRAX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 54.36 | Neutral |
| STOCH(9,6) | 36.32 | Neutral |
| STOCHRSI(14) | 27.95 | Neutral |
| MACD(12,26) | 0.0286 | Buy |
| ADX(14) | 38.37 | Buy |
| William %R | -77.12 | Neutral |
| CCI(14) | -2.9286 | Neutral |
Buy: 2
Sell: 0
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.2327
Sell
|
0.2327
Sell
|
| MA20 |
0.1853
Buy
|
0.2061
Buy
|
| MA50 |
0.1706
Buy
|
0.1933
Buy
|
| MA100 |
0.215
Buy
|
0.2467
Sell
|
| MA200 |
0.3884
Sell
|
0.4382
Sell
|
Buy: 5
Sell: 5
Neutral: 0
Summary: Neutral
According to our latest analysis, VRAX could be considered a Potential Buy, with 17 technical analysis indicators signaling 7 Buy signals, 5 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on VRAX, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 54.36 indicates that VRAX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 36.32 indicates that VRAX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 27.95 indicates that VRAX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 38.37 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -2.9286 indicates that VRAX is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term VRAX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Virax Biolabs Group Ltd financial reports and earnings history, Virax Biolabs Group Ltd (VRAX) stock could reach $6.0932 by 2030, $20.20 by 2040 and $38.87 by 2050. See the projected annual prices until 2050 of the Virax Biolabs Group Ltd stock below:
- Virax Biolabs Group Ltd (VRAX) is expected to reach an average price of $41.68 in 2035, with a high prediction of $43.42 and a low estimate of $41.71. This indicates an $18,227% rise from the last recorded price of $0.2275.
- Virax Biolabs Group Ltd (VRAX) stock is projected to chart a bullish course in 2040, with an average price target of $18.61, representing an $8,080% surge from its current level. The forecast ranges from a conservative $18.63 to a sky-high $20.20.
- Our analysts predict Virax Biolabs Group Ltd (VRAX) to jump 35,448% by 2045, soaring from $80.99 to an average price of $80.85, potentially reaching $83.93. While $80.99 is the low estimate, the potential upside is significant.
- Virax Biolabs Group Ltd (VRAX) stock is expected to climb by 2050, reaching an average of $34.18, a $14,929% jump from its current level. However, a wide range of estimates exists, with high and low targets of $38.87 and $34.22, respectively, highlighting the market's uncertainty.
Virax Biolabs Group Ltd Stock (VRAX) Year by Year Forecast
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2026
The predicted value for Virax Biolabs Group Ltd (VRAX) in 2026 is set at an average of $8.351. Estimates vary from a peak of $16.60 to a trough of $0.1027, indicating an +3,572% surge from the present price of $0.2275.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| June, 2026 | $16.10 | $16.21 | $15.53 | +6,977% |
| July, 2026 | $16.93 | $16.26 | $16.40 | +7,345% |
| August, 2026 | $16.16 | $16.34 | $16.60 | +7,003% |
| September, 2026 | $15.50 | $15.57 | $15.91 | +6,717% |
| October, 2026 | $15.43 | $15.60 | $15.64 | +6,682% |
| November, 2026 | $14.64 | $14.72 | $14.97 | +6,336% |
| December, 2026 | $13.86 | $13.89 | $14.43 | +5,991% |
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Virax Biolabs Group Ltd (VRAX) is $8.7358, with a high forecast of $13.57 and a low forecast of $3.8988. This indicates an +3,741% increase from the last price of $0.2275.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $13.06 | $13.10 | $13.57 | +5,642% |
| February, 2027 | $12.40 | $12.46 | $12.82 | +5,353% |
| March, 2027 | $11.69 | $11.75 | $12.15 | +5,041% |
| April, 2027 | $10.94 | $10.98 | $11.46 | +4,709% |
| May, 2027 | $10.25 | $10.25 | $10.63 | +4,406% |
| June, 2027 | $9.2906 | $9.3209 | $10.04 | +3,985% |
| July, 2027 | $8.6074 | $8.6134 | $9.1086 | +3,684% |
| August, 2027 | $7.8745 | $7.8877 | $8.411 | +3,362% |
| September, 2027 | $7.086 | $7.1059 | $7.6934 | +3,015% |
| October, 2027 | $6.3037 | $6.3533 | $6.8708 | +2,671% |
| November, 2027 | $5.6595 | $5.6608 | $6.1171 | +2,388% |
| December, 2027 | $3.8788 | $3.8988 | $5.4568 | +1,605% |
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2028
In 2028, Virax Biolabs Group Ltd (VRAX) is projected to reach an average price of $13.29, with a high projection of $25.78 and a low estimate of $0.8054. This indicates an +5,745% rise from the last price of $0.2275.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $3.3712 | $3.4212 | $3.6344 | +1,382% |
| February, 2028 | $2.4712 | $2.5526 | $3.1279 | +986.47% |
| March, 2028 | $1.7947 | $1.8114 | $2.1593 | +689.07% |
| April, 2028 | $1.0842 | $1.1609 | $1.4305 | +376.66% |
| May, 2028 | $24.78 | $0.8054 | $22.23 | +10,795% |
| June, 2028 | $25.83 | $26.04 | $25.26 | +11,258% |
| July, 2028 | $25.97 | $25.72 | $25.46 | +11,317% |
| August, 2028 | $25.06 | $25.24 | $25.78 | +10,920% |
| September, 2028 | $24.05 | $24.36 | $24.73 | +10,475% |
| October, 2028 | $23.94 | $23.97 | $23.82 | +10,426% |
| November, 2028 | $22.35 | $22.43 | $23.48 | +9,726% |
| December, 2028 | $21.22 | $21.26 | $22.05 | +9,230% |
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2029
The 2029 price forecast for Virax Biolabs Group Ltd Stock (VRAX) is $13.71 on average, with a high prediction of $20.95 and a low estimate of $6.4698. This represents an +5,927% increase from the previous price of $0.2275.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $19.94 | $19.98 | $20.95 | +8,666% |
| February, 2029 | $18.91 | $18.97 | $19.60 | +8,215% |
| March, 2029 | $18.07 | $18.08 | $18.48 | +7,846% |
| April, 2029 | $16.93 | $16.95 | $17.70 | +7,341% |
| May, 2029 | $15.56 | $15.57 | $16.62 | +6,741% |
| June, 2029 | $14.43 | $14.44 | $15.26 | +6,246% |
| July, 2029 | $13.35 | $13.37 | $14.12 | +5,769% |
| August, 2029 | $11.99 | $12.00 | $13.07 | +5,171% |
| September, 2029 | $10.96 | $10.98 | $11.72 | +4,719% |
| October, 2029 | $9.5879 | $9.6375 | $10.67 | +4,115% |
| November, 2029 | $8.5748 | $8.5761 | $9.3091 | +3,670% |
| December, 2029 | $6.3698 | $6.4698 | $8.28 | +2,701% |
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2030
Virax Biolabs Group Ltd Stock (VRAX) is expected to reach an average price of $18.31 in 2030, with a high forecast of $35.10 and a low forecast of $1.5081. This signifies an +7,948% surge from the last price of $0.2275.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $5.4569 | $5.5069 | $6.0932 | +2,299% |
| February, 2030 | $4.188 | $4.2694 | $5.1213 | +1,741% |
| March, 2030 | $3.2642 | $3.2733 | $3.7839 | +1,335% |
| April, 2030 | $2.2606 | $2.3245 | $2.9676 | +893.91% |
| May, 2030 | $33.92 | $1.5081 | $30.00 | +14,811% |
| June, 2030 | $35.36 | $34.93 | $35.04 | +15,446% |
| July, 2030 | $35.34 | $35.18 | $35.10 | +15,436% |
| August, 2030 | $34.49 | $34.55 | $34.97 | +15,064% |
| September, 2030 | $33.17 | $33.29 | $33.54 | +14,482% |
| October, 2030 | $32.11 | $32.14 | $32.54 | +14,018% |
| November, 2030 | $30.46 | $30.49 | $31.56 | +13,290% |
| December, 2030 | $28.82 | $28.96 | $29.96 | +12,572% |
0.67%
1.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):